Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Gibraltar Capital Management Inc.

Gibraltar Capital Management Inc. grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 116,868 shares of the biopharmaceutical company’s stock after buying an additional 1,600 shares during the period. Bristol-Myers Squibb accounts for approximately 2.9% of Gibraltar Capital Management Inc.’s holdings, making the stock its 18th biggest holding. Gibraltar Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $6,610,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Advisor OS LLC raised its holdings in Bristol-Myers Squibb by 30.2% in the fourth quarter. Advisor OS LLC now owns 5,457 shares of the biopharmaceutical company’s stock valued at $309,000 after buying an additional 1,267 shares during the period. Lake Street Advisors Group LLC boosted its stake in shares of Bristol-Myers Squibb by 20.4% during the 4th quarter. Lake Street Advisors Group LLC now owns 14,722 shares of the biopharmaceutical company’s stock valued at $833,000 after buying an additional 2,498 shares during the last quarter. Bradley & Co. Private Wealth Management LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth about $49,000. Longbow Finance SA increased its holdings in shares of Bristol-Myers Squibb by 5.0% in the 4th quarter. Longbow Finance SA now owns 54,908 shares of the biopharmaceutical company’s stock valued at $3,106,000 after acquiring an additional 2,600 shares during the last quarter. Finally, Canton Hathaway LLC lifted its position in shares of Bristol-Myers Squibb by 43.2% in the 4th quarter. Canton Hathaway LLC now owns 995 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 300 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Trading Up 0.6 %

Bristol-Myers Squibb stock opened at $58.25 on Wednesday. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.10. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The firm has a market capitalization of $118.21 billion, a PE ratio of -13.18, a PEG ratio of 2.07 and a beta of 0.45. The business’s 50-day simple moving average is $57.05 and its 200-day simple moving average is $54.56.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Equities research analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 4.26%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -56.11%.

Insiders Place Their Bets

In other news, EVP Samit Hirawat bought 1,823 shares of the business’s stock in a transaction on Friday, February 14th. The shares were purchased at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the purchase, the executive vice president now owns 63,932 shares of the company’s stock, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.09% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Leerink Partners upgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $55.00 to $73.00 in a research note on Tuesday, November 12th. Wolfe Research initiated coverage on shares of Bristol-Myers Squibb in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Bank of America reiterated a “neutral” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Daiwa Capital Markets upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Finally, Leerink Partnrs upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $57.86.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.